CKPT vs. AEON, KZR, CALC, EGRX, ALRN, ANVS, IMMX, RPHM, CELU, and EQ
Should you be buying Checkpoint Therapeutics stock or one of its competitors? The main competitors of Checkpoint Therapeutics include AEON Biopharma (AEON), Kezar Life Sciences (KZR), CalciMedica (CALC), Eagle Pharmaceuticals (EGRX), Aileron Therapeutics (ALRN), Annovis Bio (ANVS), Immix Biopharma (IMMX), Reneo Pharmaceuticals (RPHM), Celularity (CELU), and Equillium (EQ). These companies are all part of the "pharmaceutical preparations" industry.
Checkpoint Therapeutics (NASDAQ:CKPT) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, community ranking, valuation, analyst recommendations and dividends.
AEON Biopharma has lower revenue, but higher earnings than Checkpoint Therapeutics.
In the previous week, AEON Biopharma had 2 more articles in the media than Checkpoint Therapeutics. MarketBeat recorded 8 mentions for AEON Biopharma and 6 mentions for Checkpoint Therapeutics. Checkpoint Therapeutics' average media sentiment score of 0.00 beat AEON Biopharma's score of -0.15 indicating that Checkpoint Therapeutics is being referred to more favorably in the media.
22.0% of Checkpoint Therapeutics shares are owned by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are owned by institutional investors. 2.1% of Checkpoint Therapeutics shares are owned by insiders. Comparatively, 20.0% of AEON Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Checkpoint Therapeutics presently has a consensus target price of $22.60, suggesting a potential upside of 1,295.06%. AEON Biopharma has a consensus target price of $18.00, suggesting a potential upside of 916.95%. Given Checkpoint Therapeutics' higher possible upside, analysts plainly believe Checkpoint Therapeutics is more favorable than AEON Biopharma.
Checkpoint Therapeutics received 167 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 66.15% of users gave Checkpoint Therapeutics an outperform vote.
AEON Biopharma has a net margin of 0.00% compared to Checkpoint Therapeutics' net margin of -50,336.89%.
Checkpoint Therapeutics has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.Comparatively, AEON Biopharma has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.
Summary
AEON Biopharma beats Checkpoint Therapeutics on 7 of the 13 factors compared between the two stocks.
Get Checkpoint Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CKPT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CKPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Checkpoint Therapeutics Competitors List
Related Companies and Tools
